Ignite Creation Date:
2024-05-06 @ 7:53 PM
Last Modification Date:
2024-10-26 @ 3:16 PM
Study NCT ID:
NCT06175923
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-01-23
First Post:
2023-11-29
Brief Title:
Role of BMP Pathway in MDS Progression
Sponsor:
Hospices Civils de Lyon
Organization:
Hospices Civils de Lyon
Study Overview
Official Title:
Role of the BMP Pathway in Myelodysplastic Syndromes Progression and in the Transition to Acute Myeloid Leukemia
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BMP-MDS
Brief Summary:
Myelodysplastic syndromes MDS are hematological cancers that can progress to acute myelogenous leukemia AML The involvement of the microenvironment in the maintenance resistance and evolution of MDS is increasingly described
The Bone Morphogenetic Protein BMP pathway is involved in numerous functions including self-renewal of the hematopoietic stem cell compartment and the regulation of hematopoiesis via interaction with bone marrow stromal cells Investigators have demonstrated its involvement in chronic myeloid leukemia CML and AML in particular via the activation of TWIST1 ΔNp73 NANOG it is responsible for an increased state of quiescence of certain cancer stem cells and their resistance
Preliminary results based on the analysis of large databases suggest that the BMP pathway is also altered early in MDS This study explores the alteration of this pathway in MDS and its involvement in the transformation into AML
If appropriate the BMP pathway could constitute a very promising therapeutic target to combat transformation into AML
The Bone Morphogenetic Protein BMP pathway is involved in numerous functions including self-renewal of the hematopoietic stem cell compartment and the regulation of hematopoiesis via interaction with bone marrow stromal cells Investigators have demonstrated its involvement in chronic myeloid leukemia CML and AML in particular via the activation of TWIST1 ΔNp73 NANOG it is responsible for an increased state of quiescence of certain cancer stem cells and their resistance
Preliminary results based on the analysis of large databases suggest that the BMP pathway is also altered early in MDS This study explores the alteration of this pathway in MDS and its involvement in the transformation into AML
If appropriate the BMP pathway could constitute a very promising therapeutic target to combat transformation into AML
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None